Study Number	AALL1331
NCT #	NCT02101853
Dataset #	NCT02101853-D3 (Main)
PMID #	37257143

Comments: Blanks represent missing data or not applicable for analyses.
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Some data in this data submission may have been included in the NCTN/NCORP Data Archive NCT02101853-D1 and -D2 datasets and may be further updated and/or cleaned for the purposes of this publication.

Variable Number	Variable Name	Type	Label	Notes
1	USI	Character	USI	
2	consort_p1_37257143	Character	Completed risk assignment	
3	consort_p2_37257143	Character	Indicates if patient received Block 2	
4	consort_p3_37257143	Character	Indicates if patient received Block 3	
5	consort_p4_37257143	Character	Indicates if patient received Blinatumomab cycle 1	
6	consort_p5_37257143	Character	Indicates if patient received Continuation 1	
7	consort_p6_37257143	Character	Indicates if patient received Blinatumomab cycle 2	
8	consort_p7	Character	Indicates if patient received Continuation 2	
9	consort_p8	Character	Indicates if patient received Blinatumomab cycle 3	
10	consort_p9	Character	Indicates if patient received Maintenance	
11	rsn_not_proceed	Character	Reason for exclusion or not proceeding to next cycle	
12	pt_outcome_37257143	Character	Randomization status for low-risk patients	
13	age_enroll	Numeric	Age at enrollment in years	
14	age_enroll_cat	Character	Age at enrollment in years (5 categories)	
15	age_enroll_cat1	Character	Age at enrollment in years among patients with bone marrow± extramedullary disease (3 categories)	

Study Number	AALL1331	
NCT #	NCT02101853	
Dataset #	NCT02101853-D3 (Main)	
PMID #	37257143	
Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Some data in this data submission may have been included in the NCTN/NCORP Data Archive NCT02101853-D1 and -D2 datasets and may be further updated and/or cleaned for the purposes of this publication.		
16	age_dx	Numeric	Age at initial diagnosis in years	
17	age_dx_cat	Character	Age at initial diagnosis in years (5 categories)	
18	sex	Character	Sex	
19	race	Character	Race	
20	ethnicity	Character	Ethnicity	
21	siterelp	Character	Site of first relapse (3 categories)	
22	rsite1	Character	Site of first relapse	
23	rsite2	Character	Site of second relapse	
24	timerelp	Character	Time from initial diagnosis to first relapse	
25	cyto_favor	Character	Cytogenetic group, favorable or unfavorable	
26	cyto_cat	Character	Cytogenetic group	
27	cns_dx	Character	CNS status at initial diagnosis	
28	stratum_sc	Character	Stratum	
29	dfsi	Numeric	Disease-free survival from randomization	0-censor, 1-event
30	dfs_type	Character	Disease-free survival event type	
31	dfsyrs	Numeric	Years to disease-free survival from randomization	
32	osi	Numeric	Overall Survival from randomization	0-censor, 1-death

Study Number	AALL1331			
NCT #	NCT02101853			
Dataset #	NCT02101853-D3 (Main)			
PMID #	37257143			
Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Some data in this data submission may have been included in the NCTN/NCORP Data Archive NCT02101853-D1 and -D2 datasets and may be further updated and/or cleaned for the purposes of this publication.				
33	osyrs	Numeric	Years to overall survival from randomization	
34	osyrs1	Numeric	Years to overall survival from second relapse	
35	time_relp_cat1	Character	Time from initial diagnosis to relapse among patients with bone marrow± extramedullary disease	
36	mrdb1_cat	Character	End Block 1 minimal residual disease (%) positivity among patients with bone marrow± extramedullary disease	
37	timecrt	Numeric	Time from randomization to cranial radiotherapy in months	
38	relp_before_rad	Character	Indicates if patient had second relapse before planned radiation	
39	block3	Numeric	Indicates if patient received block 3	0-No, 1-Yes
40	days_block3	Numeric	Days during Block 3	
41	blinac1	Numeric	Indicates if patient received Blinatumomab Cycle 1	0-No, 1-Yes
42	days_blinac1	Numeric	Days during Blinatumomab Cycle 1	
43	blinac2	Numeric	Indicates if patient received Blinatumomab Cycle 2	0-No, 1-Yes
44	days_blinac2	Numeric	Days during Blinatumomab Cycle 2	

Study Number	AALL1331
NCT #	NCT02101853
Dataset #	NCT02101853-D3 (Main)
PMID #	37257143

Comments: Blanks represent missing data or not applicable for analyses.
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Some data in this data submission may have been included in the NCTN/NCORP Data Archive NCT02101853-D1 and -D2 datasets and may be further updated and/or cleaned for the purposes of this publication.

45	blinac3	Numeric	Indicates if patient received Blinatumomab Cycle 3	0-No, 1-Yes
46	days_blinac3	Numeric	Days during Blinatumomab Cycle 3	
47	block3anyae	Numeric	Indicates if patient experienced any grade AEs during Block 3	0-No, 1-Yes
48	block3gd3ae	Numeric	Indicates if patient experienced grade 3+ AEs during Block 3	0-No, 1-Yes
49	blinac1anyae	Numeric	Indicates if patient experienced any grade AEs during Blinatumomab Cycle 1	0-No, 1-Yes
50	blinac1gd3ae	Numeric	Indicates if patient experienced grade 3+ AEs during Blinatumomab Cycle 1	0-No, 1-Yes
51	blinac2anyae	Numeric	Indicates if patient experienced any grade AEs during Blinatumomab Cycle 2	0-No, 1-Yes
52	blinac2gd3ae	Numeric	Indicates if patient experienced grade 3+ AEs during Blinatumomab Cycle 2	0-No, 1-Yes
53	blinac3anyae	Numeric	Indicates if patient experienced any grade AEs during Blinatumomab Cycle 3	0-No, 1-Yes
54	blinac3gd3ae	Numeric	Indicates if patient experienced grade 3+ AEs during Blinatumomab Cycle 3	0-No, 1-Yes
55	anyblinaanyae	Numeric	Indicates if patient experienced any grade AEs during Blinatumomab Cycle 1, Cycle 2 or Cycle 3	0-No, 1-Yes

Study Number	AALL1331
NCT #	NCT02101853
Dataset #	NCT02101853-D3 (Main)
PMID #	37257143

Comments: Blanks represent missing data or not applicable for analyses.
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Some data in this data submission may have been included in the NCTN/NCORP Data Archive NCT02101853-D1 and -D2 datasets and may be further updated and/or cleaned for the purposes of this publication.

56	anyblinagd3ae	Numeric	Indicates if patient experienced grade 3+ AEs during Blinatumomab Cycle 1, Cycle 2 or Cycle 3	0-No, 1-Yes
57	offae	Character	Indicates if patient went off therapy due to grade 3+ AEs (tremor/seizure/confusion/ headache)	
58	grade5ae	Character	Indicates if patient experienced grade 5 AEs	